Home » Stocks » Protagonist Therapeutics

Protagonist Therapeutics, Inc. (PTGX)

Stock Price: $18.03 USD 0.07 (0.36%)
Updated Aug 10, 2020 4:00 PM EDT - Market closed
After-hours: $15.06 -2.97 (-16.45%) Aug 10, 5:36 PM

Stock Price Chart

Key Info

Market Cap 620.69M
Revenue (ttm) 16.72M
Net Income (ttm) -73.41M
Shares Out 35.67M
EPS (ttm) -2.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 10, 2020
Last Price $18.03
Previous Close $17.96
Change ($) 0.07
Change (%) 0.36%
Day's Open 18.00
Day's Range 17.68 - 18.16
Day's Volume 187,488
52-Week Range 4.47 - 19.67

More Stats

Market Cap 620.69M
Enterprise Value 418.62M
Earnings Date (est) Nov 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 35.67M
Float 28.43M
EPS (basic) -2.54
EPS (diluted) -2.55
FCF / Share -2.01
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.32M
Short Ratio 2.92
Short % of Float 4.45%
Beta 1.28
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 37.11
PB Ratio 9.36
Revenue 16.72M
Operating Income -72.38M
Net Income -73.41M
Free Cash Flow -66.05M
Net Cash 202.06M
Net Cash / Share 5.87
Gross Margin 1.38%
Operating Margin -432.79%
Profit Margin -439.00%
FCF Margin -394.91%
ROA -24.25%
ROE -58.31%
ROIC -97.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(69.21% upside)
Current: $18.03
Target: 30.50
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-99.25%54.14%----
Gross Profit0.2330.9320.06---
Operating Income-80.52-42.27-37.90-32.70-14.79-9.32
Net Income-77.19-38.92-36.96-37.74-14.93-11.22
Shares Outstanding25.8922.3617.696.500.250.23
Earnings Per Share-2.98-1.74-2.09-5.80-59.32-49.38
Operating Cash Flow-41.53-49.953.87-29.97-14.39-7.74
Capital Expenditures-0.97-0.49-0.67-0.35-0.40-0.30
Free Cash Flow-42.49-50.433.21-30.32-14.78-8.04
Cash & Equivalents13312914477.6111.930.00
Total Debt17.01-----
Net Cash / Debt11612914477.6111.930.00
Book Value79.9611312187.56-27.40-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Protagonist Therapeutics, Inc.
Country United States
Employees 80
CEO Dinesh V. Patel

Stock Information

Ticker Symbol PTGX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: PTGX
IPO Date August 11, 2016


Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat patients with moderate-to-severe Crohn's disease; and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating inflammatory bowel disease. It is also involved in researching oral and injectable peptide-based product candidates for a range of conditions, including gastrointestinal diseases. The company has a license and collaboration agreement with Janssen Biotech, Inc. for the development, manufacture, and commercialization of PTG-200 for the treatment of Crohn's disease and ulcerative colitis. Protagonist Therapeutics, Inc. was founded in 2006 and is headquartered in Newark, California.